Transforming lives in immune mediated disease
Transforming lives in immune mediated disease
Quell Therapeutics is a clinical-stage company, fuelled by curiosity and discovery, on a mission to make life better for those battling severe immune and inflammatory disease
Discover our industry-leading platform and technology
WE ARE PIONEERS
At Quell, we are reimagining the treatment of severe immune disorders.
Our goal is to leverage the unique potential of Tregs to reinstate immune balance, bringing long-lasting control to patients with severe immune diseases.
The Problem
When immune tolerance is lost
Each day, the immune system delicately navigates the balance between self-tolerance and protection against external threats.
When this equilibrium is broken, it can lead to autoimmunity, chronic inflammation, or, in the case of organ transplantation, graft rejection.
Within this intricate interplay, Tregs serve as the pivotal regulators of tolerance - dampening immune responses and applying the brakes to prevent autoreactivity, inflammation and subsequent tissue damage.
Through engineering a patient's own Tregs, Quell aims to develop treatments with the potential to transform and to save lives.
Discover our Science
Our Platform
Delivering the most functionally stable and potent targeted Tregs
with the optimal cell product at our core and a suite of innovative technologies to ensure continued trailblazing progress
Innovation Platform
Off the Shelf Treg Therapy
Faster, simpler and lower cost
Quell's iPSC allogeneic platform is set to revolutionize future cell therapies by providing a scalable, off-the-shelf Treg cell therapy solution. This ground-breaking platform harnesses the power of induced pluripotent stem cells to create universally dosable Treg cells - a faster, simpler and lower cost product to allow broader accessibility to a wider range of immune-mediated diseases.
Our Platform
Delivering the most functionally stable and potent targeted Tregs
with the optimal cell product at our core and a suite of innovative technologies to ensure continued trailblazing progress
Core Platform
Innovation Platform
Off the Shelf Treg Therapy
Faster, simpler and lower cost
Quell's iPSC allogeneic platform is set to revolutionize future cell therapies by providing a scalable, off-the-shelf Treg cell therapy solution. This ground-breaking platform harnesses the power of induced pluripotent stem cells to create universally dosable Treg cells - a faster, simpler and lower cost product to allow broader accessibility to a wider range of immune-mediated diseases.
Team & Culture
Empowered by our people
Empowered by our people
At Quell we present a calling for visionaries looking to shape the future of healthcare
